The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Bristol Myers (BMY) announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) were trading at $55, up $29.28, or 113%, on positive interim data from the phase Ib acute hemodynamic trial of its lead product candidate, TX-45.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

Preliminary findings from the phase 1 trial showed that GCC19CART, a novel CAR T-cell therapy, demonstrated clinical ...

Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers BV combined with Len + R ... Patients were stratified by CD30 expression (positive [≥1%] v negative [<1%]), ...

During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...

After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...